‘Global Spine Biologics Market Worth $3,899m In 2020’ Says Visiongain Report

30 August 2018
Pharma

Visiongain’s new report Global Spine Biologics Market Forecast 2016-2026: Demineralized Bone Matrix, BMP/Growth Factor, Bone Substitutes, Cell Based Matrices, Machined Bone, Allograft Bone, Platelet Concentrators, Traditional Fusion, Interbody Fusion, Inpatient and Outpatient Surgery Centers indicates that the global Spine Biologics market will see $3,899m in spending in 2020.

The lead analyst of the report said: “The spine biologics segment is the second largest segment of the spine surgery devices market following the spinal fusion devices. This market has huge growth potentials for market players as the use of biologics products in spine surgeries has been evolving to improve the surgical outcomes and to achieve potential fusion. Proliferation of new technologies has greater impact on the growth of this market.

We forecast the global market for spine biologics to continue its growth in the second half of the forecast period when the market will reach a value of $5,604.4 million, growing with a CAGR of 5.7% between 2014 and 2026. We anticipated the market for spine biologics to reach $5.6 billion in 2026, as promising new stem cell-based biologics products helps to push up revenue in this market.”

The 142 page report contains 125 tables, charts and graphs that add visual analysis in order to explain developing trends within the Global Spine Biologics market. Visiongain provides revenue forecasts for the period 2016-2026 as well as qualitative analyses for the leading segments of this market, categorized by type of product, type of surgery and end user.

The 142 page report offers market forecasts and analysis for 12 leading national markets and the rest of the world market. In addition, the report contains a dedicated leading companies’ chapter covering companies leading the field in the spine biologics market.

The Global Spine Biologics Market Forecast 2016-2026: Demineralized Bone Matrix, BMP/Growth Factor, Bone Substitutes, Cell Based Matrices, Machined Bone, Allograft Bone, Platelet Concentrators, Traditional Fusion, Interbody Fusion, Inpatient and Outpatient Surgery Centers report will be of value to anyone who wants to better understand the Spine Biologics market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the Spine Biologics industry.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever